US industry representative begins work in China
This article was originally published in RAJ Devices
US medtech industry association AdvaMed has announced that it now has an on-the-ground representative in China to help it address market access challenges that remain as the country reforms its healthcare system1.
You may also be interested in...
Novartis’s siRNA for lowering cholesterol was also among the 10 new medicines that the European Medicines Agency this week said should be approved in the EU.
The developers of three drugs are hoping the European Medicines Agency will decide that their products merit fast-tracking when they are submitted for review for potential pan-EU approval.
Hot on the heels of announcing it was joining Project Orbis, the UK drug regulator, the MHRA, now says it will join another international collaboration that allows drug companies to submit medicines for review by several countries at the same time.